Skip to main content
PMC home page
Biochemical Journal logoLink to Biochemical Journal
. 1994 Nov 15;304(Pt 1):43–49. doi: 10.1042/bj3040043

Recombinant alpha-L-iduronidase: characterization of the purified enzyme and correction of mucopolysaccharidosis type I fibroblasts.

E G Unger 1, J Durrant 1, D S Anson 1, J J Hopwood 1
PMCID: PMC1137449  PMID: 7998955

Abstract

Mucopolysaccharidosis type I (MPS I, Hurler and Scheie syndromes) is an autosomal recessive lysosomal storage disorder that results from a deficiency of the hydrolase alpha-L-iduronidase (IDUA) which is involved in the lysosomal degradation of both heparan sulphate (HS) and dermatan sulphate (DS). Patients with MPS I store and excrete large amounts of partially degraded HS and DS. In order to evaluate enzyme replacement therapy for MPS I patients we have expressed human IDUA cDNA in Chinese Hamster Ovary (CHO)-K1 cells utilizing a plasmid vector that places the cDNA under the transcriptional control of the human polypeptide-chain-elongation factor I alpha gene promoter. A clonal cell-line that secreted recombinant IDUA in a precursor form at approximately 2.2 micrograms/10(6) cells per day was identified. This enzyme was shown to be endocytosed into cultured MPS I fibroblasts via mannose-6-phosphate receptors and to correct the storage phenotype of these cells by enabling the lysosomal-digestion of accumulated sulphated glycosaminoglycans. The recombinant IDUA had on SDS/PAGE a molecular mass of 85 kDa and was processed to 74 kDa and smaller forms following its uptake by fibroblasts. Milligram quantities of the recombinant IDUA were immunopurified and the enzyme was shown to have pH optimum and kinetic parameters differing from those of the mature enzyme purified from human liver. The specific activity of the recombinant enzyme was shown to increase on dilution and on incubation with reducing agents. This was in contrast to the mature IDUA form (74 kDa) which did not have its activity stimulated by reducing agents or dilution.

Full text

PDF
43

Images in this article

47Figure 5
on p.47
47Figure 6
on p.47
47Figure 7
on p.47

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anson D. S., Taylor J. A., Bielicki J., Harper G. S., Peters C., Gibson G. J., Hopwood J. J. Correction of human mucopolysaccharidosis type-VI fibroblasts with recombinant N-acetylgalactosamine-4-sulphatase. Biochem J. 1992 Jun 15;284(Pt 3):789–794. doi: 10.1042/bj2840789. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Attwood P. V., Johannssen W., Chapman-Smith A., Wallace J. C. The existence of multiple tetrameric conformers of chicken liver pyruvate carboxylase and their roles in dilution inactivation. Biochem J. 1993 Mar 1;290(Pt 2):583–590. doi: 10.1042/bj2900583. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bielicki J., Freeman C., Clements P. R., Hopwood J. J. Human liver iduronate-2-sulphatase. Purification, characterization and catalytic properties. Biochem J. 1990 Oct 1;271(1):75–86. doi: 10.1042/bj2710075. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bielicki J., Hopwood J. J., Wilson P. J., Anson D. S. Recombinant human iduronate-2-sulphatase: correction of mucopolysaccharidosis-type II fibroblasts and characterization of the purified enzyme. Biochem J. 1993 Jan 1;289(Pt 1):241–246. doi: 10.1042/bj2890241. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Brown W. E., Seamon K. B. Quantitation and characterization of the trifluoroacetonyl derivative of cysteine: a useful NMR probe. Anal Biochem. 1978 Jun 15;87(1):211–222. doi: 10.1016/0003-2697(78)90587-0. [DOI] [PubMed] [Google Scholar]
  6. Clements P. R., Brooks D. A., McCourt P. A., Hopwood J. J. Immunopurification and characterization of human alpha-L-iduronidase with the use of monoclonal antibodies. Biochem J. 1989 Apr 1;259(1):199–208. doi: 10.1042/bj2590199. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Clements P. R., Brooks D. A., Saccone G. T., Hopwood J. J. Human alpha-L-iduronidase. 1. Purification, monoclonal antibody production, native and subunit molecular mass. Eur J Biochem. 1985 Oct 1;152(1):21–28. doi: 10.1111/j.1432-1033.1985.tb09158.x. [DOI] [PubMed] [Google Scholar]
  8. Clements P. R., Muller V., Hopwood J. J. Human alpha-L-iduronidase. 2. Catalytic properties. Eur J Biochem. 1985 Oct 1;152(1):29–34. doi: 10.1111/j.1432-1033.1985.tb09159.x. [DOI] [PubMed] [Google Scholar]
  9. Freeman C., Hopwood J. J. Human alpha-L-iduronidase. Catalytic properties and an integrated role in the lysosomal degradation of heparan sulphate. Biochem J. 1992 Mar 15;282(Pt 3):899–908. doi: 10.1042/bj2820899. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hopwood J. J., Muller V., Harrison J. R., Carey W. F., Elliott H., Robertson E. F., Pollard A. C. Enzymatic diagnosis of the mucopolysaccharidoses: experience of 96 cases diagnosed in a five-year period. Med J Aust. 1982 Mar 20;1(6):257–260. [PubMed] [Google Scholar]
  11. Kovacina K. S., Steele-Perkins G., Roth R. A. A role for the insulin-like growth factor II/mannose-6-phosphate receptor in the insulin-induced inhibition of protein catabolism. Mol Endocrinol. 1989 Jun;3(6):901–906. doi: 10.1210/mend-3-6-901. [DOI] [PubMed] [Google Scholar]
  12. LEABACK D. H., WALKER P. G. Studies on glucosaminidase. 4. The fluorimetric assay of N-acetyl-beta-glucosaminidase. Biochem J. 1961 Jan;78:151–156. doi: 10.1042/bj0780151. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Myerowitz R., Neufeld E. F. Maturation of alpha-L-iduronidase in cultured human fibroblasts. J Biol Chem. 1981 Mar 25;256(6):3044–3048. [PubMed] [Google Scholar]
  14. Rome L. H., Hill D. F. Lysosomal degradation of glycoproteins and glycosaminoglycans. Efflux and recycling of sulphate and N-acetylhexosamines. Biochem J. 1986 May 1;235(3):707–713. doi: 10.1042/bj2350707. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Scott H. S., Anson D. S., Orsborn A. M., Nelson P. V., Clements P. R., Morris C. P., Hopwood J. J. Human alpha-L-iduronidase: cDNA isolation and expression. Proc Natl Acad Sci U S A. 1991 Nov 1;88(21):9695–9699. doi: 10.1073/pnas.88.21.9695. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Scott H. S., Guo X. H., Hopwood J. J., Morris C. P. Structure and sequence of the human alpha-L-iduronidase gene. Genomics. 1992 Aug;13(4):1311–1313. doi: 10.1016/0888-7543(92)90053-u. [DOI] [PubMed] [Google Scholar]
  17. Scott H. S., Litjens T., Hopwood J. J., Morris C. P. A common mutation for mucopolysaccharidosis type I associated with a severe Hurler syndrome phenotype. Hum Mutat. 1992;1(2):103–108. doi: 10.1002/humu.1380010204. [DOI] [PubMed] [Google Scholar]
  18. Scott H. S., Litjens T., Nelson P. V., Thompson P. R., Brooks D. A., Hopwood J. J., Morris C. P. Identification of mutations in the alpha-L-iduronidase gene (IDUA) that cause Hurler and Scheie syndromes. Am J Hum Genet. 1993 Nov;53(5):973–986. [PMC free article] [PubMed] [Google Scholar]
  19. Shively J. E., Conrad H. E. Formation of anhydrosugars in the chemical depolymerization of heparin. Biochemistry. 1976 Sep 7;15(18):3932–3942. doi: 10.1021/bi00663a005. [DOI] [PubMed] [Google Scholar]
  20. Singh H., Derwas N., Poulos A. Very long chain fatty acid beta-oxidation by rat liver mitochondria and peroxisomes. Arch Biochem Biophys. 1987 Dec;259(2):382–390. doi: 10.1016/0003-9861(87)90504-2. [DOI] [PubMed] [Google Scholar]
  21. Taylor J. A., Gibson G. J., Brooks D. A., Hopwood J. J. alpha-L-iduronidase in normal and mucopolysaccharidosis-type-I human skin fibroblasts. Biochem J. 1991 Feb 15;274(Pt 1):263–268. doi: 10.1042/bj2740263. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES